← Inhibrx Biosciences, Inc. (INBX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Inhibrx Biosciences, Inc. (INBX)
Biological Products, (No Diagnostic Substances) · market cap $1.5B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Inhibrx Biosciences (INBX) is a small-cap biotech (156 employees, ~$1.28B market cap) focused on engineered antibody therapies, with its lead asset INBRX-106, a hexavalent OX40 agonist antibody, in Phase 3 for HNSCC and Phase 2 for broader solid tumors, alongside INBRX-109 in Phase 2 for conventional chondrosarcoma. The company carries $161.7M in cash (roughly 12.8 months of runway) and a net debt position of $13.3M, making near-term capital needs a live concern.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| INBRX-109 | Phase 2 | Conventional Chondrosarcoma |
| INBRX-106 | Phase 3 | Head and Neck Squamous Cell Carcinoma (HNSCC) |
| INBRX-106 - Hexavalent OX40 agonist antibody | Phase 2 | Solid Tumor |
Price & technical context
3-month
+0.4%
6-month
+46.1%
12-month
+190.8%
52-wk range
$28.36–$141.84
vs 50-day MA
-3.7%
vs 200-day MA
+7.7%
Realized vol
105.5%
Max drawdown
-44.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for INBX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.